![]() Bristol Myers Squibb cannot guarantee that a patient will receive assistance. Each foundation has its own eligibility criteria and evaluation process. It is important to note that charitable foundations are independent from Bristol-Myers Squibb Company.For patients without prescription drug insurance or for patients who are underinsured, BMS Access Support can make a referral to independent charitable foundations that may be able to help.Patients Without Prescription Drug Coverage or Who Are Underinsured Please contact BMS Access Support at 1-80 for details. BMS Access Support can make a referral to independent charitable foundations offering support for your specific patient.Patients insured through Federal Healthcare Programs are not eligible for co-pay assistance programs sponsored by Bristol Myers Squibb.Patients With Insurance Through Federal Healthcare Programs Please click here for full Terms and Conditions, including complete eligibility requirements. ![]() ![]() Eligible patients may pay as little as $0 per one-month supply, up to a maximum of $15,000 per calendar year.įor more information, please call BMS Access Support ® at 1-80, 8 am to 8 pm ET, Monday – Friday. The BMS Oncology Co-Pay Assistance Program helps commercially insured patients who have been prescribed select BMS medications with out-of-pocket deductibles, co-pays, or co-insurance requirements. Patients With Commercial (Private) Insurance The appropriate program will depend on the patient’s coverage. 1, 2024, about 13% of the commercial payer market will be operating under laws that ban accumulators.BMS Access Support ® can help identify financial assistance programs for eligible patients who have been prescribed REVLIMID and who need help managing the cost of treatment. The bans are not just nibbling at the edges. According to Avalere, as of January 2023, 16 states (Arizona, Arkansas, Connecticut, Delaware, Georgia, Illinois, Kentucky, Louisiana, Maine, New York, North Carolina, Oklahoma, Tennessee, Virginia, Washington and West Virginia) had banned accumulators in state-regulated health plans. State regulators and legislatures have also gotten involved. In August 2022, three patient groups - the HIV and Hepatitis Policy Institute, the Diabetes Patient Advocacy Coalition and the Diabetes Leadership Council - filed a lawsuit challenging a Trump administration decision that allowed pharmacy benefit managers to continue to use accumulator and maximizers. Many patient groups and professional organizers are opposed to accumulator programs. They have pushed back with “copay adjustment programs,” especially “copay accumulators,” which are designed to blunt the effect of the copay assistance programs by not counting their value toward patient deductibles.Īccording to Avalere Health, a healthcare consulting firm in Washington, D.C., more than 80% of the people covered by commercial insurance belong to plans that have implemented a copay accumulator and more than 70% are in plans with copay maximizers, a version of the accumulators designed to even out patient out-of-pocket costs. But pharmacy benefit managers have cried foul, saying the copay programs undercut formularies and wind up increasing the use of expensive drugs that are not any better than less expensive ones. Drugmakers use copay assistance programs to shield patients from out-of-pocket expenses - and build market share for their products in the process.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |